

Outthink. Outperform.

## Not max-ed out yet; upgrade to Buy

Supermax (SUCB) reported a strong set of results - 9MFY20 PATAMI of RM126m (+21% yoy) is above both our and consensus estimates, delivering 91% and 85% of our respective forecasts. The stronger-than-expected performance was mainly driven by higher selling prices due to the shortage of rubber gloves, in our view. As there is limited new capacity coming on stream for the next few quarters, we believe that SUCB still has room to raise selling prices. As such, we are raising our EPS forecasts by 27%-61% for FY20-21E, and raising our TP to RM5.40. Upgrade to BUY from HOLD.

### COVID-19 helped drive profit

SUCB was able to deliver a strong earnings growth for 3QFY20, as PATAMI for the quarter grew by >100% both qoq and yoy. We believe that the strong performance is mainly driven by higher ASPs, as the shortage of gloves has given SUCB the flexibility to increase selling prices. EBIT margin improved to 21.1% in 3QFY20 from 14.5% in 3QFY19. SUCB also benefited from a higher distribution margin; unlike its peers which mainly sell to distributors, SUCB also deals directly with healthcare providers, for which we had previously underestimated the margin enhancement.

### Just the beginning

We believe that there is still room to raise selling prices, as we are only expecting the overall sector to increase capacity by around 10% for 2020. Given that the outbreak has only become a serious problem starting from 2Q20, demand is likely to remain robust in the coming quarters. Hence the current margin is no doubt sustainable, in our opinion. Apart from benefiting from the price increases, SUCB would also benefit from the full contribution of Plant #12A, which was fully commissioned recently. Plant #12A has added around 2.2bn capacity (~10%) to its existing 22bn capacity.

### Upgrading to BUY with higher TP of RM5.40

We are increasing our EPS forecasts by 27%-61% for FY20-22E, to factor in a higher margin assumption (and selling price). We are also raising our TP to RM5.40, based on an unchanged 33x CY21 PER on the back of the earnings upgrade. Apart from the price increases, SUCB would also benefit from a weaker Ringgit. Key downside risk to our call: 1) sharp movement in raw-material prices, and 2) sudden movement of US\$ against MYR.

### Earnings & Valuation Summary

FYE 30 June	2018	2019	2020E	2021E	2022E
Revenue (RMm)	1,304.5	1,489.3	2,212.9	2,289.9	2,392.8
EBITDA (RMm)	210.6	230.6	351.7	387.2	312.6
Pretax profit (RMm)	161.9	172.6	311.8	347.3	273.0
Net profit (RMm)	106.7	123.8	223.5	249.1	197.1
EPS (sen)	7.8	9.1	16.4	18.3	14.5
PER (x)	58.5	50.5	27.9	25.1	31.7
Core net profit (RMm)	106.7	123.8	223.5	249.1	197.1
Core EPS (sen)	7.8	9.1	16.4	18.3	14.5
Core EPS growth (%)	58.7	16.0	80.6	11.5	(20.9)
Core PER (x)	58.5	50.5	27.9	25.1	31.7
Net DPS (sen)	3.9	4.5	7.4	8.3	6.5
Dividend Yield (%)	0.8	1.0	1.6	1.8	1.4
EV/EBITDA (x)	31.0	28.0	19.4	17.5	21.5
Chg in EPS (%)			61.0	26.9	29.5
Affin/Consensus (x)			1.5	1.3	1.1

Source: Company, Bloomberg, Affin Hwang forecast

### Results Note

## Supermax

SUCB MK  
Sector: Rubber Products

RM4.59 @ 20 May 2020

### BUY (upgrade)

Upside: 18%

### Price Target: RM5.40

Previous Target: RM4.20



### Price Performance

	1M	3M	12M
Absolute	136.6%	192.4	189.5%
Rel to KLCI	133.0%	212.7	223.8%

### Stock Data

Issued shares (m)	1,291.4
Mkt cap	5927.6/1361.3
Avg daily vol - 6mth (m)	17.2
52-wk range (RM)	1.29-4.62
Est free float	58.3%
BV per share (RM)	0.88
P/BV (x)	5.19
Net cash/ (debt) (RMm)	(265.91)
ROE (2021E)	18%
Derivatives	No
Shariah Compliant	Yes

### Key Shareholders

Thai Kim Sim	21.9%
Tan Bee Geok	16.2%

Source: Affin Hwang, Bloomberg

Ng Chi Hoong  
(603) 2146 7470  
chihoong.ng@affinhwang.com

Out think. Out perform.

Fig 1: Results Comparison

FYE 30 June (RMm)	3Q FY19	2Q FY20	3Q FY20	Qoq % chg	Yoy % chg	9M FY19	9M FY20	Yoy % chg	Comments
Revenue	361.2	385.5	447.2	16.0	23.8	1,113.4	1,202.7	8.0	The increase qoq was due to both higher selling prices and higher sales volume
Op costs	(298.6)	(325.9)	(339.9)	4.3	13.9	(921.3)	(987.4)	7.2	The increase qoq was mainly due to higher sales volume
EBITDA	62.6	59.6	107.3	80.2	71.3	192.1	215.3	12.1	Improvement qoq is mainly due to the price increases
EBITDA margin (%)	17.3	15.5	24.0	+8.5ppt	+6.7ppt	17.3	17.9	+0.6ppt	
Depn and amort	(10.4)	(12.8)	(13.1)	1.9	26.3	(32.0)	(38.5)	20.2	Higher depreciation yoy due to the new lines
EBIT	52.3	46.7	94.2	101.6	80.2	160.1	176.8	10.4	
EBIT margin (%)	14.5	12.1	21.1	+8.9ppt	+6.6ppt	14.4	14.7	+0.3ppt	
Int expense	(4.5)	(4.6)	(3.5)	(23.7)	(22.3)	(13.8)	(12.3)	(10.7)	
JV & Associates	1.7	(0.3)	4.6	>100	173.1	3.6	5.1	40.0	
EI	-	-	-	n.m	n.m	6.5	-	(100.0)	Flow through from EBITDA
Pretax profit	49.4	41.8	95.3	127.8	92.8	156.4	169.5	8.4	
Tax	(14.5)	(11.8)	(22.9)	94.2	58.6	(46.8)	(42.2)	(9.7)	
Tax rate (%)	29.2	28.2	24.1	-4.2ppt	-5.2ppt	31.7	23.1	-8.7ppt	
MI	(0.3)	0.1	(1.3)	na	273.7	(1.0)	(1.4)	42.3	
Net profit	34.6	30.2	71.1	135.6	105.3	108.7	126.0	15.9	
EPS (sen)	2.5	2.2	5.2	135.6	105.3	8.0	9.3	15.9	Above our and consensus expectations
Core net profit	34.6	30.2	71.1	135.6	105.3	104.3	126.0	20.8	

Source: Affin Hwang, Company

## Important Disclosures and Disclaimer

### Equity Rating Structure and Definitions

<b>BUY</b>	Total return is expected to exceed +10% over a 12-month period
<b>HOLD</b>	Total return is expected to be between -5% and +10% over a 12-month period
<b>SELL</b>	Total return is expected to be below -5% over a 12-month period
<b>NOT RATED</b>	Affin Hwang Investment Bank Berhad does not provide research coverage or rating for this company. Report is intended as information only and not as a recommendation

*The total expected return is defined as the percentage upside/downside to our target price plus the net dividend yield over the next 12 months.*

<b>OVERWEIGHT</b>	Industry, as defined by the analyst's coverage universe, is expected to outperform the KLCI benchmark over the next 12 months
<b>NEUTRAL</b>	Industry, as defined by the analyst's coverage universe, is expected to perform inline with the KLCI benchmark over the next 12 months
<b>UNDERWEIGHT</b>	Industry, as defined by the analyst's coverage universe is expected to under-perform the KLCI benchmark over the next 12 months

This report is intended for information purposes only and has been prepared by Affin Hwang Investment Bank Berhad (14389-U) ("the Company") based on sources believed to be reliable and is not to be taken in substitution for the exercise of your judgment. You should obtain independent financial, legal, tax or such other professional advice, when making your independent appraisal, assessment, review and evaluation of the company/entity covered in this report, and the extent of the risk involved in doing so, before investing or participating in any of the securities or investment strategies or transactions discussed in this report. However, such sources have not been independently verified by the Company, and as such the Company does not give any guarantee, representation or warranty (expressed or implied) as to the adequacy, accuracy, reliability or completeness of the information and/or opinion provided or rendered in this report. Facts, information, estimates, views and/or opinion presented in this report have not been reviewed by, may not reflect information known to, and may present a differing view expressed by other business units within the Company, including investment banking personnel and the same are subject to change without notice. Reports issued by the Company, are prepared in accordance with the Company's policies for managing conflicts of interest. Under no circumstances shall the Company, be liable in any manner whatsoever for any consequences (including but are not limited to any direct, indirect or consequential losses, loss of profit and damages) arising from the use of or reliance on the information and/or opinion provided or rendered in this report. Under no circumstances shall this report be construed as an offer to sell or a solicitation of an offer to buy any securities. The Company its directors, its employees and their respective associates may have positions or financial interest in the securities mentioned therein. The Company, its directors, its employees and their respective associates may further act as market maker, may have assumed an underwriting commitment, deal with such securities, may also perform or seek to perform investment banking services, advisory and other services relating to the subject company/entity, and may also make investment decisions or take proprietary positions that are inconsistent with the recommendations or views in this report. The Company, its directors, its employees and their respective associates, may provide, or have provided in the past 12 months investment banking, corporate finance or other services and may receive, or may have received compensation for the services provided from the subject company/entity covered in this report. No part of the research analyst's compensation or benefit was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report. Employees of the Company may serve as a board member of the subject company/entity covered in this report.

Third-party data providers make no warranties or representations of any kind relating to the accuracy, completeness, or timeliness of the data they provide and shall not have liability for any damages of any kind relating to such data.

This report, or any portion thereof may not be reprinted, sold or redistributed without the written consent of the Company.

This report is printed and published by:  
 Affin Hwang Investment Bank Berhad (14389-U)  
 A Participating Organisation of Bursa Malaysia Securities Berhad

22nd Floor, Menara Boustead,  
 69, Jalan Raja Chulan,  
 50200 Kuala Lumpur, Malaysia.

T : + 603 2142 3700  
 F : + 603 2146 7630  
 research@affinhwang.com

www.affinhwang.com